Effect of butylphthalide sequential therapy on stable Parkinson disease patients with mild cognitive im-pairment
Objective To explore the value of sequential therapy of butylphthalide in the treatment of patients with mild cognitive impairment in stable Parkinson's disease.Methods From April 2020 to December 2022,80 pa-tients with mild cognitive impairment diagnosed as stable stage of Parkinson's disease were selected by EXCEL table to carry out this clinical comparative study.The cases were grouped by random number table method,and 40 patients receiving Donepezil hydrochloride were included in the control group.In addition to the control group,40 patients re-ceiving sequential butylphthalein therapy were included in the observation group.The clinical efficacy and incidence of adverse reactions after treatment were analyzed,and the clinical indexes,psychological state,malondialdehyde(MDA)and superoxide dismutase(SOD)levels before and after treatment were evaluated.Results The clinical effect of the observation group was higher than that of the control group,the difference was statistically significant(P＜0.05).There was no significant difference in the incidence of adverse reactions between the observation group and the control group(P＞0.05).After treatment,SDS scores and SAS scores of the 2 groups were decreased,and the SDS scores and SAS scores of the observation group were lower than those of the control group,the difference was statistically signifi-cant(P＜0.05).Before treatment,there was no significant difference in UPDRS score,MMSE score,MoCA score and QOL score between the two groups(P＞0.05).After treatment,UPDRS score of the two groups decreased,while MMSE score,MoCA score and QOL score increased,and UPDRS score of the observation group was lower than that of the control group.MMSE scores,MoCA scores and QOL scores were higher than those of control group,and the dif-ferences were statistically significant(P＜0.05).Before treatment,there was no statistically significant difference in MDA and SOD between the two groups(P＞0.05).After treatment,MDA and SOD increased in the two groups,and MDA and SOD in the observation group were higher than those in the control group,the difference was statistically sig-nificant(P＜0.05).Conclusion Sequential therapy of butylphthalide in patients with mild cognitive impairment at stable stage of Parkinson's disease can not only improve their physical and mental state,but also reduce the symptoms of Parkinson's disease,promote the recovery of cognitive function,and improve the overall quality of life of patients.
Sequential therapy with butylphthalideParkinson's diseaseCognitive impairmentPsychological stateQuality of life
万方数据
